WithdrawnPhase 1NCT02059850
NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Studying Myxoid/round cell liposarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fred Hutchinson Cancer Center
- Principal Investigator
- Seth Pollack, MDFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
- Intervention
- Autologous NY-ESO-1-specific CD8-positive T Lymphocytes(biological)
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2014 – 2016
Study locations (1)
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02059850 on ClinicalTrials.govOther trials for Myxoid/round cell liposarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06644755First-in-Human Trial of DS-2243a in Participants With Advanced Solid TumorsDaiichi Sankyo
- RECRUITINGPHASE1NCT06414434BTX-A51 in Patients With Liposarcoma or CIC-rearranged SarcomaMichael Wagner, MD
- RECRUITINGPHASE1NCT06083883Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1M.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT05492682START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of CancerValo Therapeutics Oy
- ACTIVE NOT RECRUITINGPHASE2NCT04044768Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell LiposarcomaUSWM CT, LLC